• Missense mutations often impair protein folding, and thus intracellular trafficking and secretion.
Summary. Background: Missense mutations often impair protein folding and intracellular processing, which can be improved by small compounds with chaperone-like activity. However, little has been done in coagulopathies, where even modest increases of functional levels could have therapeutic implications. Objectives: To rescue the expression of factor IX (FIX) variants affected by missense mutations associated with type I hemophilia B (HB) through chaperone-like compounds. Methods: Expression studies of recombinant (r)FIX variants and evaluation of secreted levels (ELISA), intracellular trafficking (immunofluorescence) and activity (coagulant assays) before and after treatment of cells with chaperone-like compounds. Results: As a model we chose the most frequent HB mutation (p.R294Q,~100 patients), compared with other recurrent mutations associated with severe/moderate type I HB. Immunofluorescence studies revealed retention of rFIX variants in the endoplasmic reticulum and negligible localization in the Golgi, thus indicating impaired intracellular trafficking. Consistently, and in agreement with coagulation phenotypes in patients, all missense mutations resulted in impaired secretion (< 1% wild-type rFIX). Sodium phenylbutyrate (NaPBA) quantitatively improved trafficking to the Golgi and dose dependently promoted secretion (from 0.3 AE 0.1% to 1.5 AE 0.3%) only of the rFIX-294Q variant. Noticeably, this variant displayed a specific coagulant activity that was higher (~2.0 fold) than that of wild-type rFIX in all treatment conditions. Importantly, coagulant activity was concurrently increased to levels (3.0 AE 0.9%) that, if achieved in patients, would ameliorate the bleeding phenotype. Con
Introduction
Missense mutations are the main cause of human genetic disease and the most detrimental effect is exerted by amino acid changes impairing protein folding, thus leading to altered intracellular processing [1] . Protein folding is a complicated process that is assisted by chaperones, which are specialized molecules binding and stabilizing nascent polypeptides [2] .
To counteract these detrimental effects, small molecules exhibiting chaperone-like activity have shown the ability to rescue protein biosynthesis impaired by missense mutations [3] [4] [5] . Despite the therapeutic potential of these compounds, only very few attempts have been made for secreted proteins, in particular in the coagulation field, with a very limited number of mutations and molecules being challenged [6, 7] . It is worth noting that even a modest increase from barely detectable (< 1%) to appreciable (3-5%) functional protein levels in plasma of coagulation factor-deficient patients is likely to ameliorate the clinical phenotype [8] . So far, small molecules have been extensively explored to induce ribosome readthrough and rescue nonsense mutations [9] [10] [11] [12] , another relatively frequent cause of coagulopathies [13, 14] .
Here, for the first time, we investigated chaperone-like compounds to rescue factor IX (FIX) expression impaired by missense mutations that are associated with proportionally low FIX activity and antigen levels, and thus type I hemophilia B (HB) [15] . This mutation type is by far the most frequent in HB, and we addressed a panel of F9 missense mutations that includes the most represented in type I HB (p.R294Q). By extensive expression studies we detailed the defective intracellular processing of the selected FIX variants. Through a screening of chaperone-like compounds we identified sodium phenylbutyrate that, in a dose-dependent manner, appreciably improved intracellular trafficking and, most importantly, secretion of functional FIX impaired by the p.R294Q mutation.
Materials and methods

Creation of expression vectors
Expression vectors for recombinant FIX (rFIX) variants were produced by mutagenesis of human F9 cDNA, cloned into pCDNA3, as described [16] 
Cell transfection and treatment with compounds
Expression studies were performed in human embryonic kidney 293 (HEK293) cells as described [11, 17] ; 4-phenylbutyrate, sodium phenylbutyrate (NaPBA), N-acetylcysteine and ambroxol were from Sigma-Aldrich (St. Louis, MO, USA); VX-809 was from Selleckchem (Houston, TX, USA). Stable clones were treated with chaperone-like compounds in 24-well plates, and media and cell lysates collected 48 h later.
Evaluation of rFIX protein levels
Secreted rFIX variants were evaluated by ELISA through polyclonal antibodies (Affinity Biologicals, Ancaster, ON, Canada). Known concentrations of purified rFIX were used as reference. The rFIX in cell lysates was revealed by western blotting [12] .
Immunofluorescence studies
Stable clones, seeded on a 12-mm glass slide within 24-well plates and maintained for 24 h in vitamin K-supplemented medium, were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Non-specific binding sites were blocked with PBS-5% milk-0.1% Triton X-100 (blocking buffer). Polyclonal goat anti-human FIX (1:200; Affinity Biologicals), polyclonal rabbit anti-PDI (protein disulfide-isomerase) (1:200; Abcam, Cambridge, UK) and monoclonal mouse anti-GM130 (1:100; Becton Dickinson, Franklin Lakes, NJ, USA) antibodies were diluted in blocking buffer and incubated overnight at 4°C. Detection was performed by Alexa Fluor-conjugated donkey anti-goat (594 nm; FIX), anti-rabbit (488 nm; PDI) and anti-mouse (647 nm; GM130) antibodies (Thermo Fisher Scientific, Waltham, MA, USA) incubated for 1 h at room temperature. Images were acquired on the Zeiss LSM510 confocal microscope [18] .
Coagulant activity of recombinant variants
Coagulant activity of rFIX variants was assessed by activated partial thromboplastin time (APTT)-based assays as previously described [11, 12] . Coagulation times from a standard curve with serial dilutions of stably expressed wild-type rFIX (rFIX-wt) were used as reference.
Data analysis
Coagulant assays were analyzed by a two-phase decay non-linear fit of coagulation times with GraphPad Prism 5 (San Diego, CA, USA) [19] . Immunofluorescence images were analyzed by ImageJ software (https://imagej. net) [20] . Statistical differences were analyzed by t-test.
Results and discussion
Missense mutations, representing > 55% of F9 gene alterations listed in reports [13, 21] and databases (www.fac torix.org) [14] , are associated with heterogeneous phenotypes, with severe forms being caused by FIX coagulant levels below 1% of normal [15] . We focused on the p.R294Q, the most frequent F9 missense mutation (n = 97) associated with severe/moderate type I HB (Fig. 1A, B ) [22] , and thus a candidate to affect intracellular processing. As a comparison, we included a panel of Results in C and D are reported as % of rFIX-wt (mean AE standard deviation from three independent experiments). ns, not significant; *P < 0.05; **P < 0.005; wt, wild-type; Mock, cells transfected with a gutted vector; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
recurrent mutations associated with severe HB, namely the p.Y115C (n = 9), p.Y161C (n = 5) and p.Y305C (n = 9) substitutions. Mutations were characterized by expression of rFIX variants in HEK293 cells, known to properly synthesize FIX with its complex post-translational modifications [23] , and evaluation at the extracellular and intracellular level. To evaluate secretion efficiency of rFIX variants, we initially performed transient expression studies. The ELISA in conditioned media revealed extremely reduced (from~0.3% to~0.7% of rFIX-wt) secreted levels for all variants (Fig. 1C, upper panel) that displayed a size comparable to that of rFIX-wt in cell lysates (Fig. 1C, lower  panel) . To corroborate these findings, we also expressed the rFIX variants in Chinese Hamster Ovary cells, another well-established cell line to characterize coagulation factor variants [24] . In this experimental system, rFIX-wt was secreted in medium at levels (424 AE 170 ng mL À1 ) comparable to those measured from HEK293 cells (441 AE 25 ng mL À1 ), and rFIX missense variants confirmed a very inefficient secretion (from~0.2% to~0.5% of rFIX-wt) (Fig. 1D ). These data indicated that the selected missense mutations impair FIX secretion, thus demonstrating their association with severe type I deficiency and providing us with a HEK293-based experimental system to investigate rescue by chaperone-like compounds.
To overcome the intrinsic variability related to transient expression, which might confound the evaluation of treatment effects, we selected stable clones. As in the previous system, we detected very low secreted rFIX levels (< 1% of rFIX-wt) for all missense variants, which validated the experimental model. Immunostaining of rFIX, and of the endoplasmic reticulum (ER) or Golgi markers, was exploited to trace intracellular rFIX trafficking through the secretory pathway [23] . Confocal microscopy followed by analysis of the three fluorescence signals clearly localized rFIX-wt within the ER and particularly in the Golgi (Fig. 2A) , consistent with proper trafficking towards secretion. Conversely, the rFIX variant affected by the p.Y450C mutation, previously demonstrated to cause severe type I HB [16] (Fig. 2B) . The rFIX-294Q, as well as the other variants, showed a fluorescence pattern comparable to that of rFIX-450C, thus indicating impaired intracellular trafficking and supporting rFIX retention in the ER (Fig. 2C) . The data, demonstrating for the first time the pathogenic mechanisms of these mutations, were consistent with the remarkably reduced rFIX secreted levels and the associated type I HB forms.
Amino acid changes can have pleiotropic effects and, besides secretion, they also frequently impair function, a particularly critical issue for proteins with enzymatic activity. As a matter of fact, the combination of reduced secretion and functional impairment is the determinant of coagulation phenotype in patients [16, 24] . In addition, functional impairment would make unsuccessful therapeutic attempts based on promoting intracellular protein processing and secretion, as in the case of chaperone-like compounds. We therefore evaluated coagulant properties of rFIX missense variants in FIX-deficient plasma systems through APTT-based assays. As shown in Fig. 3(A) , the specific coagulant activity, referred to as the ratio between coagulant activity and secreted protein levels, was undetectable for the rFIX-115C and rFIX-161C variants and barely detectable for the rFIX-305C (0.04 AE 0.01). Intriguingly, the rFIX-294Q mutant displayed a specific coagulant activity that was higher (~2.0 fold) than that of rFIX-wt. All these elements make the rFIX-294Q variant a promising candidate to explore chaperone-like compounds.
Screening for rescue demonstrated that the 4-phenylbutyrate, VX-809, N-acetylcysteine and ambroxol compounds were ineffective at any concentration tested (data not shown). Intriguingly, NaPBA, which did not affect the rFIX-wt expression (Fig. 4A, left panel) , appreciably improved secretion of the rFIX-294Q variant with a dosedependent effect (Fig. 4A , left/middle panels). In particular, as compared with rFIX-wt, secreted levels for the rFIX-294Q variant increased from 0.3 AE 0.1% without treatment to 1.5 AE 0.3% at the highest NaPBA concentration tested (2 mM), as revealed by two different polyclonal ELISA settings. Consistently, investigations at the Fig. 2 . Evaluation of intracellular trafficking of rFIX variants. Immunofluorescence studies were conducted in stably transfected HEK293 cells. Stable clones were isolated (n°48 for each rFIX variant) and seeded in multi-well plates in the presence of G418 (500 lg mL À1 ) as selection agent and 5 lg mL À1 vitamin K. Investigation by polyclonal ELISA revealed very low secreted rFIX levels for all variants. Fluorescently labelled secondary antibodies were used to visualize rFIX (red signal) as well as PDI (ER, green) or GM130 (Golgi, blue) protein markers. Image magnifications (white square) for each channel as well as for the integration of the three signals (merge) are shown. The HEK293 clones expressing rFIX-wt (A) and rFIX-450C (B) proteins were used as controls for normal or defective rFIX expression of the investigated missense variants (C), respectively. HEK293 cells alone were used as negative control (À). Selected regions (image magnifications, white dotted lines) were analyzed for co-localization of the rFIX signal (red) relative to the ER (PDI, green) and Golgi (GM130, blue) as a function of the distance (lm) of the analyzed region (three-color plots). Histograms report the ratio of the distribution of the rFIX fluorescence in the Golgi and ER that was estimated from at least 10 cells for each variant and is expressed as mean AE standard deviation (****P < 0.0001; n.d., not detectable). rFIX, recombinant factor IX; PDI, protein disulfide-isomerase; ER, endoplasmic reticulum; GM130, Golgi matrix protein 130. Indeed, at variance with untreated rFIX-294Q-expressing cells, the overlapping of the two signals was clearly detectable after treatment with NaPBA and the co-localization of rFIX fluorescence intensity was quantitatively improved (Fig. 4B, histograms) . Noticeably, improvement of rFIX-294Q secretion was paralleled by an increase in coagulant activity in medium from NaPBA-treated cells, as indicated by the appreciable, and dose-dependent, effect on coagulation times (Fig. 4A, right panel) . Specifically, treatment resulted in a shortening of coagulation times from 80 AE 0.1 s in untreated conditions to 76 AE 4.7, 68 AE 7 and 62 AE 3 s upon treatment with 0.5, 1 and 2 mM NaPBA, respectively. As compared with rFIX-wt activity, this corresponded to an increase in coagulant activity levels from 0.5 AE 0.04% to 3.0 AE 0.9% at the highest dose (2 mM). Interestingly, for all treatment conditions, the rFIX-294Q variant showed an increased specific activity (2.2 AE 0.3, 2.1 AE 0.1 and 1.9 AE 0.2, respectively) in comparison with rFIX-wt (Fig. 3B) , a feature that magnifies the functional impact of the NaPBAmediated rescue. The same rescue profile was observed in an independent rFIX-294Q-expressing clone.
Structure-function studies indicated that arginine 294 maps in a region involved in the interaction with activated FVIII [25] . Whereas previous investigations did not permit clear definition of the specific activity of the p.R294Q variant [22, 26, 27] , the low protein levels achieved in our recombinant system do not favor a proper comparison by a fine biochemical characterization of the variant. It is worth noting that the 'gain-of-function' feature is also suggested by inspection of the FIX variant database (www.factorix.org) that reports several patients with FIX activity levels slightly exceeding antigen levels, and a large proportion of patients with a moderate bleeding phenotype. This finding resembled the paradigmatic example of the p.R384X nonsense mutation upon drug-induced readthrough, which was strongly favored by the increased specific activity of the resulting missense variant [11] . Overall, these data demonstrate that NaPBA appreciably counteracts the detrimental effects of the p.R294Q mutation and improves rFIX intracellular trafficking and secretion of a functional FIX protein.
Altogether, our data detail molecular mechanisms underlying type I HB, characterized by defective intracellular trafficking and ER retention of the rFIX missense variants. For the first time we explored the functional impact of a panel of chaperone-like compounds in HB. Through complementary approaches in cellular models we provided experimental evidence, at the intracellular and secreted protein levels, on the ability of NaPBA to rescue, in a dose-dependent manner, FIX biosynthesis and function impaired by the F9 p.R294Q, the most frequent type I HB mutation. Intriguingly, the functional impact of NaPBA-mediated rescue on the p.R294Q change was magnified by the improved specific activity of the secreted molecule. These features led to a coagulant activity (~3%) that, if achieved in HB patients, would favor the transition from a severe/moderate to a moderate/mild clinical picture and potentially alleviate the bleeding tendency. Taking into account the p.R294Q Results are reported as mean AE standard deviation from three independent experiments. As negative control we measured coagulation times in medium from untransfected HEK293 cells untreated or treated with NaPBA (0.5, 1 and 2 mM), which provided overlapping results. NaPBA, sodium phenylbutyrate.
frequency and its responsiveness to NaPBA that, albeit for different purposes [28] , is approved for use in humans and can be orally administered, these data make NaPBA a candidate as an affordable 'personalized' therapeutics, particularly in countries or settings with poor access to standard therapies. It is worth noting that the number of patients affected by this mutation (Fig. 1B) , increased both by recurrence at a CpG dinucleotide and potentially by founder effects [29, 30] , is very likely to be underestimated. Our data also suggest that rescue at the functional and as % of rFIX-wt (middle and right panels) from three independent experiments (mean AE standard deviation). ns, not significant; *P < 0.05; ***P ≤ 0.0005; ****P < 0.0001. (B) Localization of the rFIX-294Q variant in the absence (À) or in the presence (+) of 2 mM NaPBA. Co-localization of the rFIX signal (red) relative to the ER (PDI, green) and Golgi (GM130, blue) as well as of rFIX distribution in the Golgi and ER (results are reported by histograms as mean AE standard deviation; *P < 0.05) was analyzed as in Fig. 2 . NaPBA, sodium phenylbutyrate; ER, endoplasmic reticulum; GM130, Golgi matrix protein 130; PDI, protein disulfide-isomerase.
level of severe FIX mutations is not a frequent finding, and requires a systematic analysis to find suitable candidates. We propose to extend this expression platform to the numerous but individually-rare missense mutations leading to severe type I hemophilia to select those that are responsive to chaperone-like compounds, which would lay the foundation for further studies in animal models to assess the therapeutic potential. 
